TYRA
Tyra Biosciences, Inc. NASDAQ Listed Sep 15, 2021$28.32
-2.58%
vs $29.07
Mkt Cap $1.7B
52w Low $8.98
61.1% of range
52w High $40.65
50d MA $32.84
200d MA $26.18
P/E (TTM)
-14.1x
EV/EBITDA
—
P/B
6.5x
Debt/Equity
0.0x
ROE
-46.3%
P/FCF
-17.7x
RSI (14)
30.90
ATR (14)
$1.98
Beta
0.96
50d MA
$32.84
200d MA
$26.18
Avg Volume
894.9K
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
2656 State Street · Carlsbad, CA 92008 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | AMC | -0.60 | -0.64 | -6.7% | 36.19 | -0.4% | +0.9% | +1.5% | -3.7% | -5.3% | -1.1% | — |
| Mar 2, 2026 | AMC | -0.54 | -0.57 | -5.6% | 32.52 | -3.4% | +1.5% | +6.8% | -2.1% | +1.4% | -3.7% | — |
| Nov 5, 2025 | AMC | -0.50 | -0.50 | +0.0% | 14.82 | -0.6% | -3.6% | +0.3% | +1.3% | +4.3% | +2.3% | — |
| Aug 14, 2025 | AMC | -0.53 | -0.47 | +11.3% | 10.70 | +5.1% | +0.3% | +0.7% | -5.6% | +0.4% | +14.3% | — |
| May 8, 2025 | AMC | -0.49 | -0.47 | +4.1% | 10.07 | -0.3% | +0.2% | +1.7% | -2.7% | -3.1% | +2.0% | — |
| Mar 27, 2025 | AMC | -0.48 | -0.43 | +10.4% | 9.66 | +8.7% | +1.1% | -4.8% | -6.2% | -0.8% | -4.0% | — |
| Nov 7, 2024 | AMC | -0.40 | -0.41 | -2.5% | 17.15 | -2.7% | -6.1% | +0.7% | -1.8% | -1.3% | +3.8% | — |
| Aug 7, 2024 | AMC | -0.41 | -0.32 | +22.0% | 19.50 | +3.2% | +4.3% | -1.3% | +0.7% | +6.3% | +0.4% | — |
| May 9, 2024 | AMC | -0.46 | -0.35 | +23.9% | 17.76 | +2.7% | -2.3% | +6.6% | +0.4% | -0.8% | +3.6% | — |
| Mar 19, 2024 | AMC | -0.48 | -0.53 | -10.4% | 16.10 | +9.4% | +7.9% | -3.7% | -0.1% | -1.5% | -1.9% | — |
| Nov 7, 2023 | AMC | -0.35 | -0.49 | -40.0% | 12.16 | -3.0% | -1.3% | -3.0% | +1.0% | -0.6% | +5.5% | — |
| Aug 10, 2023 | AMC | -0.34 | -0.31 | +8.8% | 15.11 | +0.0% | +1.9% | +0.7% | +0.0% | -3.9% | -4.6% | — |
| May 4, 2023 | AMC | -0.37 | -0.28 | +24.3% | 12.78 | +5.5% | -2.8% | +8.7% | +1.9% | -6.8% | -4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Wolfe Research | Initiates | Peer Perform | — | $35.66 | $35.08 | -1.6% | -5.3% | -1.1% | -1.1% | -1.7% | +3.4% |
| Mar 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $38.18 | $38.67 | +1.3% | -2.7% | -1.7% | -0.5% | +1.1% | +3.6% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.99 | $28.07 | +0.3% | +4.0% | +1.0% | +6.6% | +0.8% | +5.4% |
| Feb 13 | Wedbush | Maintains | Outperform → Outperform | — | $29.19 | $29.41 | +0.8% | -4.1% | +4.0% | +1.0% | +6.6% | +0.8% |
| Feb 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $31.02 | $31.72 | +2.3% | +0.7% | -1.5% | -4.3% | +5.2% | -1.6% |
| Feb 3 | Jefferies | Maintains | Buy → Buy | — | $31.02 | $31.72 | +2.3% | +0.7% | -1.5% | -4.3% | +5.2% | -1.6% |
| Jan 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.91 | $31.51 | +1.9% | -1.7% | -0.7% | +4.1% | -1.0% | +4.1% |
| Dec 16 | Wedbush | Maintains | Outperform → Outperform | — | $22.12 | $22.56 | +2.0% | +3.8% | -1.6% | +1.7% | +11.0% | -0.5% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.70 | $11.72 | +0.2% | +0.1% | +2.5% | +5.3% | +1.9% | -4.0% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.57 | $9.53 | -0.4% | +1.6% | +3.4% | -0.5% | -3.9% | +3.1% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.77 | $9.48 | -3.0% | -4.8% | -6.2% | -0.8% | -4.0% | -6.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.19 | $13.40 | +1.6% | -4.5% | +1.6% | -0.1% | +3.1% | -2.7% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.20 | $15.00 | -1.3% | -0.7% | +5.6% | +5.0% | -3.5% | +0.2% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.11 | $16.02 | -0.6% | +0.7% | -1.8% | -1.3% | +3.8% | -5.8% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.89 | $20.28 | +2.0% | -15.0% | -5.6% | +4.4% | -1.7% | +0.2% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.93 | $22.30 | +1.7% | -9.3% | -15.0% | -5.6% | +4.4% | -1.7% |
| Oct 25 | Wedbush | Maintains | Outperform → Outperform | — | $28.61 | $23.98 | -16.2% | -23.3% | -9.3% | -15.0% | -5.6% | +4.4% |
| Oct 18 | BofA Securities | Upgrade | Neutral → Buy | — | $25.98 | $27.00 | +3.9% | +5.2% | +3.8% | -0.7% | +0.3% | +1.3% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.04 | $22.19 | +0.7% | -5.4% | +3.8% | -1.6% | -1.5% | +4.6% |
| Sep 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $23.20 | $24.00 | +3.4% | +3.4% | +1.5% | -3.0% | +0.1% | -1.6% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $19.50 | $20.12 | +3.2% | +4.3% | -1.3% | +0.7% | +6.3% | +0.4% |
| Aug 8 | Wedbush | Maintains | Outperform → Outperform | — | $19.50 | $20.12 | +3.2% | +4.3% | -1.3% | +0.7% | +6.3% | +0.4% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.70 | $16.83 | +0.8% | +1.6% | +0.8% | +4.0% | +2.4% | -0.5% |
| Jul 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.70 | $16.83 | +0.8% | +1.6% | +0.8% | +4.0% | +2.4% | -0.5% |
| Jul 3 | Wedbush | Maintains | Outperform → Outperform | — | $16.70 | $16.83 | +0.8% | +1.6% | +0.8% | +4.0% | +2.4% | -0.5% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.75 | $17.97 | +1.2% | +7.2% | +4.0% | -0.1% | +1.1% | +1.1% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.35 | $17.61 | +1.5% | +6.6% | +0.4% | -0.8% | +3.6% | -4.4% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.76 | $18.24 | +2.7% | -2.3% | +6.6% | +0.4% | -0.8% | +3.6% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $17.76 | $18.24 | +2.7% | -2.3% | +6.6% | +0.4% | -0.8% | +3.6% |
| Mar 21 | Wedbush | Maintains | Outperform → Outperform | — | $17.37 | $17.45 | +0.5% | -3.7% | -0.1% | -1.5% | -1.9% | +0.9% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.10 | $17.61 | +9.4% | +7.9% | -3.7% | -0.1% | -1.5% | -1.9% |
| Dec 29 | Wedbush | Maintains | Outperform → Outperform | — | $13.90 | $14.58 | +4.9% | -0.4% | +1.4% | -9.9% | -4.0% | -4.4% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.45 | $13.96 | +3.8% | +8.3% | -3.9% | -0.7% | -0.4% | +1.4% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.16 | $11.80 | -3.0% | -1.3% | -3.0% | +1.0% | -0.6% | +5.5% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.11 | $15.11 | +0.0% | +1.9% | +0.7% | +0.0% | -3.9% | -4.6% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $15.11 | $15.11 | +0.0% | +1.9% | +0.7% | +0.0% | -3.9% | -4.6% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.82 | $14.81 | -0.1% | -2.8% | +1.4% | +1.4% | -3.3% | -2.2% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.42 | $12.14 | -2.3% | +8.7% | +1.9% | -6.8% | -4.1% | +1.0% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.78 | $13.48 | +5.5% | -2.8% | +8.7% | +1.9% | -6.8% | -4.1% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.17 | $15.50 | +2.2% | +1.8% | +3.2% | +0.1% | -0.1% | +1.7% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.60 | $14.36 | +5.6% | +10.3% | +1.2% | -0.6% | -19.9% | +7.8% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.77 | $13.11 | +2.7% | -4.3% | -0.7% | +12.1% | +10.3% | +1.2% |
| Feb 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.30 | $13.75 | +3.4% | -0.9% | +2.0% | +0.7% | -3.4% | +7.4% |
| Jun 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.27 | $6.88 | +9.7% | +11.3% | +2.4% | -8.3% | +10.8% | +11.8% |
| Mar 8 | Jefferies | Upgrade | Hold → Buy | — | $10.96 | $11.93 | +8.9% | +3.3% | +6.8% | -7.5% | -1.7% | -3.9% |
| Nov 8 | Jefferies | Downgrade | Buy → Hold | — | $28.39 | $28.95 | +2.0% | +2.3% | -3.0% | -1.6% | +1.7% | -2.3% |
| Oct 11 | TD Cowen | Maintains | Outperform → Outperform | — | $16.26 | $15.95 | -1.9% | -5.3% | +1.7% | +4.6% | -0.7% | +0.4% |
| Oct 11 | Jefferies | Maintains | Buy → Buy | — | $16.26 | $15.95 | -1.9% | -5.3% | +1.7% | +4.6% | -0.7% | +0.4% |
| Oct 11 | BofA Securities | Maintains | Buy → Buy | — | $16.26 | $15.95 | -1.9% | -5.3% | +1.7% | +4.6% | -0.7% | +0.4% |
No insider trades available.
8-K · 2.02
!! High
Tyra Biosciences, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences appointed a board member with significant biopharmaceutical experience, including prior roles at Blueprint Medicines (acquired by Sanofi) and other therapeutic companies.
Apr 17
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing content is incomplete metadata/technical specifications rather than substantive financial information about State Street (STT) or Tyra Biosciences (TYRA).
Apr 2
8-K
Tyra Biosciences, Inc. -- 8-K Filing
I cannot provide a meaningful one-sentence analysis because the summary contains only technical XBRL metadata and filing administrative information rather than substantive business news or events affecting Tyra Biosciences investors.
Mar 4
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences reported 2025 year-end financial results and corporate progress updates for its FGFR-focused precision medicine pipeline, with CEO Todd Harris emphasizing the company's science-driven development strategy.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 7,747,648 | $297M | Added | Mar 2026 |
| 2 | Janus Henderson Group Plc | 3,890,589 | $149M | New | Mar 2026 |
| 3 | Farallon Capital Management Llc | 3,580,818 | $137M | New | Mar 2026 |
| 4 | Alta Partners Management Company, L.p. | 3,823,425 | $101M | Reduced | Dec 2025 |
| 5 | Vanguard Capital Management Llc | 1,125,970 | $43M | New | Mar 2026 |
| 6 | Barclays Plc | 833,399 | $32M | Added | Mar 2026 |
| 7 | Deerfield Management Company, L.p. | 549,000 | $21M | New | Mar 2026 |
| 8 | Woodline Partners Lp | 301,040 | $12M | New | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 247,270 | $9M | New | Mar 2026 |
| 10 | Raymond James Financial Inc | 247,098 | $9M | Added | Mar 2026 |
| 11 | Millennium Management | 221,581 | $8M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 218,508 | $8M | Added | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 209,922 | $8M | Added | Mar 2026 |
| 14 | Marshall Wace, Llp | 197,748 | $8M | Reduced | Mar 2026 |
| 15 | Stempoint Capital Lp | 193,177 | $7M | New | Mar 2026 |
| 16 | Bnp Paribas Financial Markets | 190,039 | $7M | Added | Mar 2026 |
| 17 | Algert Global Llc | 188,010 | $7M | Added | Mar 2026 |
| 18 | Morgan Stanley | 237,796 | $6M | Reduced | Dec 2025 |
| 19 | Bnp Paribas Asset Management Holding S.a. | 128,860 | $5M | Reduced | Mar 2026 |
| 20 | Invesco Ltd. | 109,052 | $4M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.68B
Enterprise Value
$1.44B
P/E (TTM)
-14.09x
Forward P/E
—
PEG Ratio
-0.39x
P/B
6.51x
P/S
—
P/FCF
-17.71x
EV/EBITDA
—
Shares Out
59.6M
Financials (TTM)
Revenue
$0
Net Income
-$119.9M
EBITDA
-$119.4M
Free Cash Flow
-$95.3M
Op Cash Flow
-$95.1M
EPS Basic
$-2.01
EPS Diluted
$-2.01
EPS Forward
$-2.39
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$282.6M
Total Liab.
$23.4M
Total Equity
$259.2M
Cash
$256.0M
LT Debt
$5.3M
Book Value/Sh
$4.35
Debt/Equity
0.02x
Current Ratio
14.67
Quick Ratio
14.67
Returns & Growth
ROE
-46.3%
ROA
-42.4%
ROIC
-50.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
-33.1%
Price Returns
2W
-8.5%
1M
-3.9%
3M
+0.3%
6M
+48.1%
12M
+267.1%
Technicals
52W High
$40.65
52W Low
$8.98
50d MA
$32.84
200d MA
$26.18
RSI (14)
30.90
ATR (14)
$1.98
Beta
0.96
Avg Volume
895K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$50.50
High
$59.00
Low
$42.00
Median
$51.50
Data updated apr 27, 2026 6:20am
· Source: financialmodelingprep.com